跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/JPRN-jRCT2031200245
JPRN-jRCT2031200245进行中（未招募）1 期

A Phase 1/2 Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) - BRUI

Tsai E. Donald0 个研究点目标入组 30 人开始时间: 2020年12月15日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症

试验速览

阶段
1 期
状态
进行中（未招募）
发起方
入组人数
30
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable（—）
性别
All

入选标准

  • •1. Histologically confirmed B-cell malignancy (e.g., CLL/SLL, WM, NHL) failed or intolerant to either 2 prior standard of care regimens given in combination or sequentially OR have received 1 prior BTK containing regimen when a BTK inhibitor is approved as first line therapy. For phase 1 confirmation of recommended dose in Japan, patients whose standard therapies are no longer effective or are not considered appropriate or safe in the opinion of the Investigator, are eligible
  • •2. During dose escalation and DLT assessment: Adequate hematologic status that meets pre-defined criteria on or within 7 days of C1D1 before treatment
  • •3. After phase 1 dose escalation and DLT assessment: Responsive to transfusion support if given for thrombocytopenia or anemia
  • •4. Eastern Cooperative Oncology Group (ECOG) 0-1
  • •5. At least 20 years of age
  • •6. Confirmation of availability of tumor sample obtained after most recent treatment
  • •7. Adequate hepatic function with test results that meet all the pre-defined criteria
  • •8. Adequate renal function defined as creatinine clearance >= 30 mL/ minute using Cockcroft/Gault Formula
  • •9. Ability to swallow tablets and comply with outpatient treatment, laboratory monitoring, and required clinic visits for the duration of study participation
  • •10. Willingness of men and women of reproductive potential to observe conventional and effective birth control methods with failure rates of < 1% for the duration of treatment and for 6 months following the last dose of study treatment

排除标准

  • •1. Investigational agent or anticancer therapy within 5 half-lives prior to planned start of LOXO-305 except therapeutic monoclonal antibody treatment must be discontinued a minimum of 4 weeks prior to the first dose of LOXO-305
  • •In addition, no concurrent investigational therapy is permitted
  • •2. Major surgery within 4 weeks prior to planned start of LOXO-305
  • •3. Radiotherapy with a limited field of radiation for palliation within 7 days of the first dose of study treatment, except for patients receiving radiation to more than 30% of the bone marrow or receiving whole brain radiotherapy, which must be completed at least 4 weeks prior to the first dose of study treatment
  • •4. Patients requiring therapeutic anticoagulation with warfarin
  • •5. Any unresolved toxicities from prior therapy greater than CTCAE (version 5.0) Grade 1 at the time of starting study treatment except for alopecia
  • •6. History of allogeneic or autologous stem cell transplant (SCT) or CAR-T therapy within the last 60 days or with any of the following:
  • •a. Active graft versus host disease (GVHD);
  • •b. Cytopenias from incomplete blood cell count recovery post-transplant;
  • •c. Need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms of neurotoxicity > Grade 1 from CAR-T therapy;
  • •d. Ongoing immunosuppressive therapy
  • •7. Known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of disease may be eligible if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval
  • •8. Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP]) where new therapy introduced or concomitant therapy escalated within the 4 weeks prior to study enrollment is required to maintain adequate blood counts
  • •9. Clinically significant, uncontrolled cardiac, cardiovascular disease or history of myocardial infarction within 6 months prior to planned start of LOXO-305, or observed pre-defined ECG findings during Screening
  • •10. Active uncontrolled systemic bacterial, viral, fungal or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which in the opinion of the Investigator and the Sponsor makes it undesirable for the patient to participate in the trial. This includes interstitial lung disease (ILD), severe dyspnea at rest, or requiring oxygen therapy. Screening for chronic conditions is not required. Patients who have a history of ILD are excluded
  • •11. Tested positive for Human Immunodeficiency Virus (HIV) is excluded (due to potential drug-drug interactions between anti-retroviral medications and LOXO-305 and risk of opportunistic infections with both HIV and irreversible BTK inhibitors). For patients with unknown HIV status, HIV testing will be performed at Screening
  • •12. Clinically significant active malabsorption syndrome or other condition likely to affect GI absorption of the study drug
  • •13. Current treatment with certain strong cytochrome P450 3A4 (CYP3A4) inhibitors or inducers and/or strong P-gp inhibitors
  • •14. Treatment with PPIs within 7 days of starting LOXO-305
  • •15. Pregnancy or lactation at time of screening. Pregnancy and lactation within 6 months of last dose of LOXO-305 is prohibited. Patients who have stopped breast feeding can be enrolled
  • •16. Active second malignancy unless in remission with li

研究者

发起方
Tsai E. Donald

相似试验

进行中（未招募）
1 期
An Early Phase Study with the Drug LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)MedDRA version: 20.1 Level: LLT Classification code 10008976 Term: Chronic lymphocytic leukemia System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10003908 Term: B-cell small lymphocytic lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10029547 Term: Non-Hodgkin's lymphoma System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-003340-24-FRoxo Oncology, Inc.190
进行中（未招募）
1 期
An Early Phase Study with the Drug LOXO-305 in Patients with PreviouslyTreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL) or Non-Hodgkin Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)and Non-Hodgkin Lymphoma (NHL)MedDRA version: 21.1Level: PTClassification code: 10003908Term: B-cell small lymphocytic lymphoma Class: 100000004864MedDRA version: 22.0Level: PTClassification code: 10029547Term: Non-Hodgkin's lymphoma Class: 100000004864MedDRA version: 21.0Level: LLTClassification code: 10008976Term: Chronic lymphocytic leukemia Class: 10029104
CTIS2023-509270-37-00oxo Oncology Inc.938
进行中（未招募）
1 期
An Early Phase Study with the Drug LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)MedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10003908Term: B-cell small lymphocytic lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10029547Term: Non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-003340-24-ITOXO ONCOLOGY INCORPORATED295
进行中（未招募）
1 期
An Early Phase Study with the Drug LOXO-305 in Patients with PreviouslyTreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma(CLL/SLL) or Non-Hodgkin Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Non-Hodgkin Lymphoma (NHL)MedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10003908Term: B-cell small lymphocytic lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 22.0Level: PTClassification code 10029547Term: Non-Hodgkin's lymphomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2018-003340-24-GBoxo Oncology, Inc.850
进行中（未招募）
1 期
A Phase 1 study on the effects of LOXO-292 (study drug) in patients with advanced solid tumorsDose escalation: Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor refractory to standard of care therapy, or for whom no standard of care therapy is available.Dose expansion: Male or female patients age 12 years or older with a locally advanced or metastatic solid tumor with evidence of a RET gene alteration in tumor and/or blood.MedDRA version: 20.0Level: LLTClassification code 10065252Term: Solid tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10027105Term: Medullary thyroid cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2017-000800-59-NLoxo Oncology, Inc.570